Email: email@example.comTelephone: Tel: +44 (0) 20 7882 3546
Mangesh Thorat graduated from the B.J. Medical College and was awarded MBBS degree by Pune University in 1999.
He subsequently completed his general surgical training at King Edward Memorial Hospital, Mumbai and Tata Memorial Hospital, Mumbai, India.
In 2002, he was awarded post-graduate qualifications (MS and DNB) in general surgery by Mumbai University, Mumbai, India (MS: Master of Surgery) and by the National Board of Examinations, New Delhi, India (DNB: Diplomate of the National Board). He then obtained further training in general surgical oncology and specialist training in breast surgery at Tata Memorial Hospital, which is the largest tertiary cancer centre in India.
In late 2006, Mangesh moved to Indiana University School of Medicine, Indianapolis, Indiana, USA to conduct research on breast cancer biomarkers.
He joined Centre for Cancer Prevention at the Wolfson Institute of Preventive Medicine, London in 2009 to continue his work on breast cancer biomarkers, with special focus on DCIS, a pre-invasive stage of breast cancer. He is specifically trying to identify biomarkers that will allow us to differentiate between DCIS that recurs or progresses to invasive breast cancer and DCIS that does not. This reasearch will eventually allow us to spare a large majority of DCIS patients from adjuvant treatments like radiotherapy and Tamoxifen and thereby avoid side effects of these treatments. His other research interests include cancer epidemiology and prevention, particularly the role of aspirin in cancer prevention; prognostic biomarkers in prostate cancer; and clinical trials in breast cancer. He also serves as the Deputy Director (Clinical) of the Barts Clinical Trials Unit.
Mangesh is a recipient of ASCO Merit Award in years 2007 and 2008, Wellcome Trust Value-in-person award in 2009 and SABCS Clinical Scholar Award in 2015. He has also received travelling fellowships from the American Association of Cancer Research (AACR), the International Agency for Research in Cancer (IARC), the European Organisation for Research and Treatment of Cancer (EORTC) and the Lynn Sage Foundation.
Mangesh served as a member of the Cancer Research UK (CRUK) Clinical Trials Advisory Awards Committee (CTAAC), the then main funding committee of CRUK overseeing the award of grant funding of the majority of cancer treatment research trials in the UK. He also serves on the executive board of the International Cancer Prevention Society (ICAPS) and on the steering committee of Early Cancer Detection Europe (ECaDE). He is a member of the American Society of Clinical Oncology (ASCO), AACR, the National Academy of Medical Sciences, India and the Indian Breast Group.
Mangesh is an Associate Editor for International Journal of Surgery and he is an Editorial Consultant for the Lancet. He acts as a peer reviewer (publons.com/a/1178863/) for more than a dozen academic journals in the fields of oncology, surgery and breast diseases, for the UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme, the Netherlands Organisation for Health Research and Development (ZonMW) and also for the Ireland Health Research Board (HRB). He has been named as reviewer of the month by the International Journal of Surgery and has been awarded Peer Review Certificate of Excellence by the Breast Journal.
Mangesh mentors students at the Barts and The London School of Medicine & Dentistry and is also involved in student assessment at entry into medical school and in exit exams. He also serves as the Faculty for the European School of Oncology and Ulm University: Certificate of Competence in Breast Cancer Programme.
- Recurrence in DCIS
- Predictors studies
- Technical evaluation of the Xpert assay in general screening population
- Evaluation of CCP score as a prognostic marker in DCIS
- Prophylactic use of aspirin
- Gynaecological extension study for the follow-up of a subset of HPV-015 study subjects
- Study to evaluate the safety immunogenicity and efficacy of GSK biologicals
- Role of Aspirin in Cancer Prevention.
- Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes.
- Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.
- COX-2 expression does not correlate with microvessel density in breast cancer.
- Revision surgery for breast cancer: single-institution experience.
- What caused the decline in US breast cancer incidence?
- Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
- FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
- Radiation therapy for ductal carcinoma in situ: is it really worth it?
- Does primary tumor location have prognostic significance in operable breast cancer?